Findings

What do systematic reviews say?

1,230 questions · 1,303 findings · 326 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 73 · 5.6%GRADE not reported 21 · 1.6%Very low 497 · 38.1%Low 403 · 30.9%Moderate 245 · 18.8%High 64 · 4.9%

Pregabalin vs placebo at end of treatment

Fatigue · patients with fibromyalgia

1 finding from 1 review

Anticonvulsants for fibromyalgia 2013 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 3195 participants
High

Pregabalin vs placebo at end of treatment

Participant‐reported sleep problems (scale: 0 to 28; higher scores indicate more sleep problems) · patients with fibromyalgia

1 finding from 1 review

Anticonvulsants for fibromyalgia 2013 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 3139 participants
High

Resistance training vs aerobic exercise training

Physical function · patients with fibromyalgia

1 finding from 1 review

Resistance exercise training for fibromyalgia 2013 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 86 participants
Low

Ventilation feedback training plus exercise vs exercise

Health‐related quality of life (Change in CRQ Dyspnoea) CRQ · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Breathing exercises for chronic obstructive pulmonary disease 2012 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 73 participants
Moderate

Intervention not reported

Vespid Quality of Life Questionnaire ‐ end of treatment Scale from 0 to 7, where a higher score indicates less quality of life impairment. · adults and children with a previous allergic reaction to an insect sting

1 finding from 1 review

Venom immunotherapy for preventing allergic reactions to insect stings 2012 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 112 participants
Moderate

Intervention not reported

Pain (short term) WOMAC scale from 0 to 20 points (higher is worse pain). · Patients with peripheral joint osteoarthritis

1 finding from 1 review

Acupuncture for peripheral joint osteoarthritis 2010 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 1835 participants
Low

Intervention not reported

Function (long term) WOMAC scale from 0 to 68 points (higher is worse function). · Patients with knee osteoarthritis

1 finding from 1 review

Acupuncture for peripheral joint osteoarthritis 2010 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1398 participants
High

Intervention not reported

Function (short term) WOMAC scale from 0 to 68 points (higher is worse function). · Patients with peripheral joint osteoarthritis

1 finding from 1 review

Acupuncture for peripheral joint osteoarthritis 2010 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 1767 participants
Low

Intervention not reported

Pain (long term) WOMAC scale from 0 to 20 points (higher is worse pain). · Patients with peripheral joint osteoarthritis

1 finding from 1 review

Acupuncture for peripheral joint osteoarthritis 2010 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1399 participants
High

Intervention not reported

Function (long term) WOMAC scale from 0 to 68 points (higher is worse function). · Patients with peripheral joint osteoarthritis

1 finding from 1 review

Acupuncture for peripheral joint osteoarthritis 2010 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1398 participants
High

Intervention not reported

Pain (short term) WOMAC scale from 0 to 20 points (higher is worse pain). · Patients with knee osteoarthritis

1 finding from 1 review

Acupuncture for peripheral joint osteoarthritis 2010 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 1773 participants
Low

Intervention not reported

Function (short term) WOMAC scale from 0 to 68 points (higher is worse function). · Patients with knee osteoarthritis

1 finding from 1 review

Acupuncture for peripheral joint osteoarthritis 2010 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 1767 participants
Low

Intervention not reported

Pain (long term) WOMAC scale from 0 to 20 points (higher is worse pain). · Patients with knee osteoarthritis

1 finding from 1 review

Acupuncture for peripheral joint osteoarthritis 2010 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1399 participants
High

Augmented subscapularis transposition vs subscapularis transposition alone during total shoulder arthroplasty

Pain The Hospital for Special Surgrery 100‐point scoring system. Scale from: 0 to 30 (higher is better). · Patients with rheumatoid shoulder

1 finding from 1 review

Surgical interventions for the rheumatoid shoulder 2010 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
Low

Augmented subscapularis transposition vs subscapularis transposition alone during total shoulder arthroplasty

Function The Hospital for Special Surgery 100‐point scoring system. Scale from: 0 to 20 (higher is better). · Patients with rheumatoid shoulder

1 finding from 1 review

Surgical interventions for the rheumatoid shoulder 2010 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
Low

Augmented subscapularis transposition vs subscapularis transposition alone during total shoulder arthroplasty

Range of motion The Hospital for Special Surgery 100‐point scoring system . Scale from: 0 to 25 (higher is better). · Patients with rheumatoid shoulder

1 finding from 1 review

Surgical interventions for the rheumatoid shoulder 2010 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
Low

Total Shoulder Arthroplasty vs hemiarthroplasty

Disability/Function (ASES) American Shoulder and Elbow Surgeons Shoulder Score. Scale from: 0 to 100 (Higher is better). · patients with Shoulder osteoarthritis

1 finding from 1 review

Surgery for shoulder osteoarthritis 2010 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 88 participants
Moderate

LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term

Global state: No clinically important improvement ‐ global evaluation ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia

LOW DOSE (greater than or equal to 2‐<4 mg/day) probably leads to higher global state: No clinically important improvement ‐ global… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 1.32 [1.06, 1.64]
2 studies · 172 participants
Moderate

LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term

Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia

LOW DOSE (greater than or equal to 2‐<4 mg/day) showed no clear difference in adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS:… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.81 [0.37, 1.75]
2 studies · 173 participants
Moderate

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: Any reasons ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.78 [0.58, 1.06]
2 studies · 496 participants
Moderate